The top 12 VC firms most actively investing in early-stage AI startups

  • Artificial intelligence is one of the buzziest technologies of the past 20 years. 
  • Since 2000, investors have poured roughly $407 billion into AI startups, per data from PitchBook. 
  • In that time frame, the top 12 VC firms most active in early-stage AI investing by deal count have collectively closed a total of 708 Series A and B rounds, according to the data analytics firm. 
  • Visit Business Insider’s homepage for more stories.

Over the past two decades, artificial intelligence has quickly become one of the most buzzy technologies. 

Giants like IBM have doubled-down on AI-backed offerings, while a rush of startups have emerged that are trying to use the tech to overhaul operations ranging from stocking shelves to supply chain negotiations.

Along with that has come a bonanza of venture capital funding that has created so-called unicorns like Indigo Ag, UiPath, and SenseTime. In the past 20 years, investors have poured

Read More

Identification of this epigenetic process highlights potential drug treatment strategies for early-stage disease treatment — ScienceDaily

New findings suggest that late-onset Alzheimer’s Disease is driven by epigenetic changes — how and when certain genes are turned on and off — in the brain. Results were published today in Nature Genetics.

Research led by Raffaella Nativio, PhD, a former research associate of Epigenetics, Shelley Berger, PhD, a professor of Genetics, Biology and Cell and Developmental Biology and Director of the Epigenetics Institute, and Nancy Bonini, PhD, a professor of Biology and Cell and Developmental Biology, all in the Perelman School of Medicine at the University of Pennsylvania, used post-mortem brain tissue to compare healthy younger and older brain cells to those with Alzheimer’s Disease. The team found evidence that epigenetic regulators disable protective pathways and enable pro-disease pathways in those with the disease.

“The last five years have seen great efforts to develop therapeutics to treat Alzheimer’s disease, but sadly, they have failed in the clinic

Read More